Table 3

Comparison of PedACR and ASAS domains after baseline adjustment

Week 4

Week 8

Week 12

Treatment

P-value*


Physicians' Global

Adalimumab

2.97 +/- 0,53

2.44 +/- 0.53

2.67 +/- 0.54

5.81#

Placebo

4.43 +/- 0.57

4.43 +/- 0.57

4.31 +/- 0.57

Difference (95% confidence Interval)

-1.47 +/- 0.78

-2.00 +/- 0.78

-1.64 +/- 0.79

0.021


Parents' Global

Adalimumab

3.45 +/- 0.62

2.86 +/- 0.62

2.85 +/- 0.63

5.78

Placebo

5.62 +/- 0.66

4.75 +/- 0.66

5.24 +/- 0.67

Difference (95% confidence Interval)

-2.17 +/- 0.91

-1.89 +/- 0.91

-2.39 +/- 0.93

0.014


No. Active Joints

Adalimumab

1.72 +/- 0.49

1.31 +/- 0.49

1.99 +/- 0.5

4.31

Placebo

2.59 +/- 0.52

3.65 +/- 0.52

2.83 +/- 0.53

Difference (95% confidence Interval)

-0.87 +/- 0.72

-2.35 +/- 0.72

-0.84 +/- 0.73

0.032


No. LOM Joints

Adalimumab

1.60 +/- 0.47

1.78 +/- 0.47

1.84 +/- 0.48

3.34

Placebo

2.38 +/- 0.50

2.65 +/- 0.50

2.01 +/- 0.52

Difference (95% confidence Interval)

-0.78 +/- 0.69

-0.87 +/- 0.69

-0.17 +/- 0.71

0.198


CHAQ

Adalimumab

0.57 +/- 0.12

0.42 +/- 0.12

0.44 +/- 0.12

0.98

Placebo

0.80 +/- 0.12

0.75 +/- 0,12

0.74 +/- 0.13

Difference (95% confidence Interval)

-0.22 +/- 0.17

-0.34 +/- 0.17

-0.30 +/- 0.17

0.079


CRP

Adalimumab

0.99 +/- 2.77

3.92 +/- 2.77

1.98 +/- 2.89

10.34

Placebo

5.91 +/- 3.05

8.69 +/- 3.05

9.72 +/- 3.05

Difference (95% confidence Interval)

-4.92 +/- 4.14

-4.76 +/- 4.14

-7.74 +/- 4.23

0.103


Spinal inflammation

Adalimumab

2.60 +/- 0.56

2.64 +/- 0.56

2.05 +/- 0.56

4.73

Placebo

3.56 +/- 0.60

3.51 +/- 0.60

3.50 +/- 0.60

Difference (95% confidence Interval)

-0.97 +/- 0.83

-0.87 +/- 0.83

-1.45 +/- 0.83

0.179


Pain Score

Adalimumab

3.60 +/- 0.59

3.60 +/- 0.59

3.23 +/- 0.60

5.84

Placebo

4.38 +/- 0.63

3.98 +/- 0.63

4.33 +/- 0.64

Difference (95% confidence Interval)

-0.78 +/- 0.87

-0.38 +/- 0.87

-1.11 +/- 0.88

0.360


Patients' Global

Adalimumab

4.50 +/- 0.54

3.97 +/- 0.54

3.76 +/- 0.55

6.38

Placebo

5.44 +/- 0.58

4.70 +/- 0.58

4.82 +/- 0.59

Difference (95% confidence Interval)

-0.94 +/- 0.80

-0.74 +/- 0.80

-1.06 +/- 0.81

0.210


BASFI

Adalimumab

2.53 +/- 0.47

2.38 +/- 0.47

2.14 +/- 0.48

4.00

Placebo

3.36 +/- 0.50

3.28 +/- 0.50

3.09 +/- 0.51

Difference (95% confidence Interval)

-0.84 +/- 0.69

-0.90 +/- 0.69

-0.95 +/- 0.70

0.171


*Total treatment difference, repeated measurement design. # Baseline adjusted value. $ ANCOVA analysis.

Horneff et al. Arthritis Research & Therapy 2012 14:R230   doi:10.1186/ar4072

Open Data